Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829843 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL17688155 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2548198 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14268316 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL924034 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL931109 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4144733 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL927049 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12908138 | 0.92 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12238524 | 0.92 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426770-B2 | Process for the preparation of Lurasidone hydrochloride | Jubilant Generics Limited (IN) | 2019-10-01 | — | — | US | disclosed |
| US-20170246165-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE | Jubilant Generics Limited (IN) | 2017-08-31 | — | — | US | disclosed |
| WO-2013132511-A1 | NOVEL POLYMORPH OF LURASIDONE HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2013-09-12 | — | — | WO | disclosed |
| WO-2011162562-A2 | [6+5] FUSED BICYCLES AS A THROMBIN ANTAGONIST, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE BICYCLES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-12-29 | — | — | WO | disclosed |
| US-5780632-A | Imide derivatives and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| EP-0464846-B1 | Imide derivatives, and their production and use | SUMITOMO PHARMA (JP) | 1998-04-22 | — | — | EP | disclosed |
| US-5532372-A | Imide derivatives, and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| EP-0464846-A1 | Imide derivatives, and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246165-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE | FFAR3, FAR1, PRLHR | KDM4E 3240/4885USP2 3603/4885ALDH1A1 479/4885 |
| US-10426770-B2 | Process for the preparation of Lurasidone hydrochloride | FFAR3, REN, LSS | KDM4E 3399/4885USP2 3569/4885ALDH1A1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.